Skip to main content

Table 2 Demographic and clinical variables of MS patients and healthy controls (HC)

From: Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

 

MS

n=195

HC

n=60

Sex (M/F)

66/129

21/39

Age

43.1±11.3

39.9±8.5

Disease duration (months)

104.9+93.2

--

Age at onset

34.5+10.3

--

EDSS

2 (0-6.0)

--

Disease subtype

CIS

24

--

RRMS

129

--

SPMS

6

--

PPMS

36

--

Treatments

DMD

  FNb

36

--

  GA

18

--

  NTZ

22

--

  FTY

20

--

Experimental drug

  EGCG

6

--

Untreated

  Untreated

93

--

  1. M male, F female, EDSS Expanded Disability Status Scale, CIS clinically isolated syndrome, RRMS relapsing-remitting MS, SPMS secondary-progressive MS, PPMS primary-progressive MS, DMD disease-modifying drug, IFNb interferon beta, GA glatiramer acetate, NTZ natalizumab, FTY fingolimod, EGCG epigallocatechin-gallate